<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03510741</url>
  </required_header>
  <id_info>
    <org_study_id>PILL-Sodium Benzoate &amp; NAC-001</org_study_id>
    <nct_id>NCT03510741</nct_id>
  </id_info>
  <brief_title>Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.</brief_title>
  <official_title>A Multicentre 12-week Randomised Double-blind Placebo Controlled Feasibility Trial of Sodium Benzoate and/or N-acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pakistan Institute of Living and Learning</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pakistan Institute of Living and Learning</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine if the addition of Sodium Benzoate and / or NAC to TAU will be
      acceptable and tolerable and result in overall improvement of symptoms, social and cognitive
      functioning in patients with early schizophrenia spectrum disorder.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>This will be a 2x2 factorial design trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind placebo controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of intervention ( including recruitment rates and drop outs)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Feasibility estimates of delivering the intervention including recruitment rates and drop outs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall improvement in symptoms using the Positive and Negative Syndrome Scale (PANSS) total score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The PANSS is measured on a 7-point scale, and is a 30-item structured clinical interview assessing symptom severity over the previous week. The PANSS scale has a maximum score of 210 and a minimum of 30. Higher scores indicate higher severity of illness.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Improvement in positive and/or negative symptoms subscales measured using the PANSS.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The PANSS is measured on a 7-point scale, and is a 30-item structured clinical interview assessing symptom severity over the previous week. The PANSS scale has a maximum score of 210 and a minimum of 30. Higher scores indicate higher severity of illness.</description>
  </other_outcome>
  <other_outcome>
    <measure>Improvement on Clinical Global Impression (CGI) Scale and Social and Occupational Functioning Assessment (SOFA) scales.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical Global Impression (CGI) Scale is an observer rated clinical severity measure. The minimum score is 1 and maximum 7. Higher scores indicate severity of illness. Social and Occupational Functioning Assessment (SOFA) scale is a measure of current functioning, with scores ranging from 0 to 100. Higher scores represent higher functioning</description>
  </other_outcome>
  <other_outcome>
    <measure>Improvement in cognitive functioning as measured using CogState Schizophrenia Battery.</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizophreniform Disorders</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Sodium Benzoate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Benzoate added to TAU will be administered at 1000mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-Acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-Acetylcysteine added to TAU 1000 mgs twice daily dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo added to TAU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Benzoate Plus N-Acetylcysteine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Benzoate</intervention_name>
    <description>Sodium Benzoate will be administered at 1000mg daily</description>
    <arm_group_label>Sodium Benzoate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>N-Acetylcysteine 1000 mgs twice daily dose</description>
    <arm_group_label>N-Acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo added to TAU</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Benzoate Plus N-Acetylcysteine</intervention_name>
    <description>Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose</description>
    <arm_group_label>Sodium Benzoate Plus N-Acetylcysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male/Female patients aged between 18-35 years.

          2. Diagnosis of schizophrenia confirmed by SCID interview meeting DSM-V criteria for
             schizophrenia, schizophreniform or schizoaffective psychosis.

          3. Stable on medication for the past four weeks

          4. In contact with mental health services

          5. Within 5 years of diagnosis of psychotic illness

          6. Able to demonstrate the capacity to provide informed consent as assessed by their own
             clinician

          7. Able to complete the required evaluations and take oral medication.

          8. Effective contraceptive precautions (either the use of barrier methods or the oral
             contraceptive pill) to be taken by women of child-bearing age. A negative pregnancy
             test will be required in order to meet inclusion criteria.

        Exclusion Criteria:

          1. Prior history of intolerance or serious side effects to Sodium Benzoate or
             N-acetylcystine.

          2. Concomitant use of Ascorbic acid

          3. Active substance abuse (except nicotine or caffeine) or dependence within the last
             three months according to DSM-V criteria.

          4. Relevant CNS or other medical disorders.

          5. Pregnant or breast feeding

          6. Diagnosis of Moderate to Severe Learning Disability

          7. Relevant current or past haematological, hepatic, renal, neurological or other medical
             disorder in the opinion of the principal investigator (PI) or the responsible
             clinician, that may interfere with the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imran B Chaudhry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziauddin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ameer B Khoso</last_name>
    <phone>021-35871845</phone>
    <email>ameer.bukhsh@pill.org.pk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Balochistan Institute of Behavioral Science</name>
      <address>
        <city>Quetta</city>
        <state>Balochistan</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof. Ghulam Rasool</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Psychiatry, Rawalpindi</name>
      <address>
        <city>Rawalpindi</city>
        <state>Islamabad</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof. Fareed A Minhas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Abbasi Shaheed Hsopital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Sohail Ahmed</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Civil Hospital Karachi</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof. Raza Ur Rehman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karwan e Hayat</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Ajmal Kazmi</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008 Sep 1;64(5):361-8. doi: 10.1016/j.biopsych.2008.03.004. Epub 2008 Apr 23.</citation>
    <PMID>18436195</PMID>
  </reference>
  <reference>
    <citation>Chaudhry IB, Husain N, Drake R, Dunn G, Husain MO, Kazmi A, Hamirani MM, Rahman R, Stirling J, Deakin W. Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. Ther Adv Psychopharmacol. 2014 Jun;4(3):110-6. doi: 10.1177/2045125313511487.</citation>
    <PMID>25057343</PMID>
  </reference>
  <reference>
    <citation>Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi SM, Moghadam M, Gharibi F, Mirshafiee O, Akhondzadeh S. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2013 Nov-Dec;36(6):185-92. doi: 10.1097/WNF.0000000000000001.</citation>
    <PMID>24201233</PMID>
  </reference>
  <reference>
    <citation>Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry. 2013 Dec;70(12):1267-75. doi: 10.1001/jamapsychiatry.2013.2159.</citation>
    <PMID>24089054</PMID>
  </reference>
  <reference>
    <citation>Lin CH, Lin CH, Chang YC, Huang YJ, Chen PW, Yang HT, Lane HY. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Biol Psychiatry. 2017 Dec 26. pii: S0006-3223(17)32297-7. doi: 10.1016/j.biopsych.2017.12.006. [Epub ahead of print]</citation>
    <PMID>29397899</PMID>
  </reference>
  <reference>
    <citation>Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, Dursun S, Dunn G, Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol. 2012 Sep;26(9):1185-93. doi: 10.1177/0269881112444941. Epub 2012 Apr 23.</citation>
    <PMID>22526685</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Sodium Benzoate</keyword>
  <keyword>N-Acetylcysteine</keyword>
  <keyword>NMDA receptor</keyword>
  <keyword>Psychopharmacology</keyword>
  <keyword>Anti-oxidant</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Sodium Benzoate</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

